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SYNTHESIS AND CHARACTERIZATION OF GOLD NANOPARTICLES
COMBINED WITH CURCUMIN AND ITS EFFECT ON EXPERIMENTAL
OSTEOARTHRITIS IN MICE
W. N. Silva Campos, V.S. Marangoni, D.A. Sonego, M.A. Andrade,
E.M. Colodel, R.L. de Souza, Sr.. FEDERAL Univ. of Mato Grosso, Cuiaba,
Brazil
Purpose: The aim of study was the synthesis and characterization of a
system combining gold nanoparticles (AuNPs) to curcumin and eval-
uate its therapeutic potential in an experimental model of osteoarthitis
(OA) in mice by destabilization of the medial meniscus (DMM).
Methods: Thirty two C57BL6 strain male mice, 8 weeks of age, were
used. For the experimental induction of osteoarthitis we used DMM
destabilization technique proposed by Glasson et al. (2007). For the
synthesis of AuNPs we used the hydrochloride polyallylamine (PAH) as
a stabilizer and sodium borohydride as a reducer agent and character-
izations were performed by UV-VIS spectroscopy, dynamic light scat-
tering (DLS) and determination zeta potential. Four groups were
formed, each with eight animals, named as A (360 mg of AUNP-PAH), B
(20 mg of curcumin), C (360mg of AUNP-PAH-Curcumin) and D (sham)
thus distributed in accordance with the administered therapy. All ani-
mals were treated with three applications by intra-articular injection,
every 15 days, with the beginning of the treatment was given on day 14
after induction of OA. After 6 weeks of induction of OA, the animals
were euthanized. All knee joint (KJ) were ﬁxed in 10% buffered formalin
for 24 hours and decalciﬁed in EDTA solution monosodium 15% for two
weeks. They were then processed according to routine procedures and
the slides stained with hematoxylin and eosin (H&E) and Safranin O fast
green to evaluate the concentration of proteoglycans. These were
assessed by 2 independent observers in a blind study, using the criteria
established by Mankin et al. (1971). By which a score of each joint was
obtained by calculating the formula, standardized by the evaluation
system of Osteoarthritis Research Society International (OARSI), andestablished by Bao et al. (2009) and Rutgers et al. (2010), thus, each KJ
received a score ranging from 0 to 24. Data were analyzed for normal
distribution using the Kolmogorov-Smirnov test. Therefore, normal
datawere submitted to analysis of variance, and, in cases of signiﬁcance,
means were compared using the Tukey test. For all statistical analysis
was adopted the 5% signiﬁcance level.
Results: Histological analyzes showed a clear distinction of articular
cartilage damage among the different groups. Focal discontinuity of
cartilage surface area and erosion with loss of surface lesions were
found more often in groups A (360 mg of AUNP-PAH) and B (20 mg of
curcumin), and loss of proteoglycans, as evidenced by decreased
safranin O staining fast green. KJ in group C (360mg of AUNP-PAH-
Curcumin), there was edema and ﬁbrillation of the cartilage surface
were the most frequent changes, emphasizing greater dial proteogly-
cans. While in the D (sham) group, there were injuries such as
microfractures with presence of ﬁbrocartilage, remodeling and bone
repair. With regard to the mean values score, there was a greater value
in group D KJ, with a mean score of 18.25. In addition, there was
signiﬁcant difference (p 0.05) between these groups. C group animals
showed a signiﬁcant decrease (p <0.001) in their scoring average
values in the control group, however there was no statistical difference
with the other groups.
Conclusions: The results show the importance of the study and
development of new nanodrugs. Despite the solutions studied have
shown similarity to each other, one should consider that animals
treatedwith the solution of AUNP-PAH-Curcumin, presented less severe
in the histological lesions. Further studies evaluating the expression of
antiinﬂammatory genes and pro-inﬂammatory, catabolic and anabolic
mediators are needed to demonstrate the effective role of this ther-
apeutic option in the treatment of OA.
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THE EFFECTS OF SIMVASTATIN ON THE SYMPTOMS OF KNEE
OSTEOARTHRITIS(KOA) DURING A 3-MONTH TREATMENT COURSE
IN A SAMPLE OF IRAQI PATIENTS
S. Salman, A.A. Mohammad. Coll. of Med., Baghdad, Iraq
Purpose: Osteoarthritis is the most common form of arthropathy.
Matrix metalloproteinases (MMPs) and proinﬂammatory cytokines
such as interleukin-1 (IL-1), IL-6, and tumor necrosis factor alpha (TNF-
a) play an important role in this condition. Statins show non lipid
modeﬁable effects, pleiotropic effects, which could be responsible for
their anti oxidative and anti inﬂammatory effect.
Methods: One hundred thirty (130) patients were randomly assigned to
receive oral simvastatin 20 mg once daily in (group A¼n 62), or placebo
(group B ¼n 68). The efﬁcacy outcome measure was the change in the
Western Ontario and McMaster Universities Osteoarthritis Index
(WOMAC) including the pain, stiffness and physical function subscales.
Results: The mean pain score at ﬁrst visit (baseline) was (8.6±2.2) in
group A, vs. (6.98±2.2) in group B, P<0.001. At the second visit after one
month the pain scores in both groups were lowered down. Two month
later the pain score in group A decreased more while in group B was
slightly increased. After three month Pain score in group A continued to
decrease (5.14±2.9), while in group B there was a smaller change than
baseline with a mean difference of only (0.6 ± 0.57). The comparison in
mean differences of the baseline score vs. the last visit (after three
month) showed a signiﬁcantly higher change of pain score in group A
than in group B. The same trends had been observed in scales of stiff-
ness, physical function and total WOMAC, and the mean changes in
WOMAC scales in group A than group B.
Conclusions: The ﬁndings of this study indicate that simvastatin at the
oral once-daily dosage of 20 mg is more effective than placebo in
treating knee OA symptoms.
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DO PHYSICIANS TREAT OSTEOARTHRITIS PROPERLY IN CHINA:
ANALYSIS OF 67382 OUT-PATIENTS FROM PEKING UNIVERSITY
PEOPLE'S HOSPITAL
H. Zhang, L. Jiang, Z. Li, X. Dong, Q. Zhong, J. Lin. Peking Univ. People’s
Hosp., Beijing, China
Purpose: There is a high prevalence of osteoarthritis(OA) in old pop-
ulation, and physicans usually treat OA based on the guideline recom-
mended by OARSI. Until now, there is no report about the treatment in
Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416A398China. In this study, we aim to analysis the treatment of OA in China and
its Rationality.
Methods: The study enrolled all out-patients prescriptions for the
treatment of osteoarthritis in Peking University People's Hospital in
2012. Statistical method was applied to analyze the characters of the
treatment for OA, and the differences of the choice of medications
caused by different clinical departments.
Results: A total of 67382 prescriptions involving 25410 osteoarthritis
out- patients were enrolled in this study. The incidence of OA- related
visits to the hospital was 2.6 times per year per person. 51 medications
were given, categorized into 8 groups according to 2008 OARSI hip and
knee osteoarthritis recommendations:①topical NSAIDs and capsaicin;
②acetaminophen; ③NSAIDs; ④weak opioids; ⑤intra-articular(IA)
injections; ⑥glucosamine; ⑦anti-osteoporosis drugs;⑧traditional
Chinese medicine(TCM). As many as 23 species of TCM were involved,
seconded by anti-osteoporosis drugs(9 species). Among all the drugs,
TCM was the most commonly prescribed(61.3%), seconded by glucos-
amine(50.6%). The study mainly involved rheumatology department,
orthopedics department, pain management department, and depart-
ment of traditional Chinese medicine. Different specialists prescribed
differently, while rheumatologists may prefer NSAIDs(24.6%) and glu-
cosamine(78.9%) more, orthopedics prefer NSAIDs(28.3%), glucos-
amine(60.4%) and TCM(66.1%), doctors from pain management
department may give more weak opioids(17.7%), glucosamine(60.4%)
and IA agents(86.2%), and traditional Chinese doctors mainly prescribe
traditional Chinese medicine(90.3%). 83.3% of all prescriptions include
oral medications, 41.5% include topical agent. Rheumatologists and
orthopedics give more oral medications, doctors from pain manage-
ment department prefer IA agents. Doctors from traditional Chinese
medicine department use more topical agent.
Conclusions: Physicians in China prefer to use glucosamine and tradi-
tional Chinese medicine to treat OA, which is lack of clear guidelines.
Compared with the physicians from the traditional Chinese medine
department and the pain management department, rheumatologists
and orthopedics treatment OA based on guidelines more.
Therapy: Biological
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PHASE 1 STUDIES OF ANTI-INTERLEUKIN-1 DUAL-VARIABLE
DOMAIN IMMUNOGLOBULIN IN HEALTHY SUBJECTS AND PATIENTS
WITH OSTEOARTHRITIS
S.X. Wang y, W. Liu y, P. Jiang y, M. Okun y, R.A. Preston z, C.J. Lozada z,
D. Carter y, J.K. Medema y. yAbbVie Inc, North Chicago, IL, USA; zMiller
Sch. of Med., Univ. of Miami, Miami, FL, USA
Purpose: Interleukin (IL)-1 is a potent catabolic cytokine that plays an
important role in the pathogenesis and progression of osteoarthritis
(OA). Preclinical proof of concept for simultaneous inhibition of IL-1a
and IL-1bwas demonstrated by both cartilage protection and increased
tolerance to mechanical nociceptive pain. Two phase 1 clinical trials
investigated the use of a novel human dual-variable
domainimmunoglobulin (DVD-Ig™) simultaneously targeting IL-1a
and IL-1b (ABT-981).
Methods: ABT-981 was evaluated in a randomized, double-blind, single
ascending dose (SAD), placebo-controlled trial in 56 healthy subjects
and in a randomized, double-blind, multiple ascending dose (MAD),
placebo-controlled trial in 36 patients with mild to moderate knee OA
(NCT01668511). In the SAD trial, each cohort received a single intra-
venous (IV) or subcutaneous (SC) dose of ABT-981 (0.3, 1, 3, and 10 mg/
kg IV or 0.3, 1, and 3mg/kg SC) or placebo in a 6:2 ratio. In theMAD trial,
cohorts 1-3 received ABT-981 (0.3, 1, or 3 mg/kg) or placebo in a 7:2
ratio every 2 weeks (EOW) for 4 SC injections total, and cohort 4
received ABT-981 (3 mg/kg) or placebo in a 7:2 ratio every 4 weeks
(E4W) for 3 SC injections total. Safety, tolerability, pharmacokinetics
(PK), anti-drug antibodies (ADAs), and biomarkers were assessed
through day 85 in the SAD trial and through day 113 for the ﬁrst 3
cohorts and through day 127 for the fourth cohort in the MAD trial. In
the MAD trial, a panel of serum/urine biomarkers of target engagement,
inﬂammation and joint degradation were compared between ABT-981-
treated and placebo groups from day 1 to 57.
Results: The incidence of adverse events (AEs) was similar with single-
dose ABT-981 vs placebo via IV (66.7% vs 50.0%) or SC (55.6% vs 66.7%)
routes and with multiple SC doses of ABT-981 vs placebo (53.6% vs62.5%). The majority of AEs were mild or moderate and considered not
or probably not related to study drug. The most common AE with ABT-
981 vs placebo was diarrhea via IV (20.8% vs 12.5%) and headache via SC
(22.2% vs 0%) in the SAD trial, and injection-site reaction (17.9% vs 0%) in
the MAD trial. No infusion reactions or injection-site reactions occurred
in the SAD trial. In the MAD trial, absolute neutrophil count (ANC)
decreased dose-dependently with ABT-981 dosing, starting at 48 hours
and reaching nadir by 14 days, with lowest ANC values (2.1-2.3/mm3)
observed with 3 mg/kg. Only 1 patient had a transient grade 2 neu-
tropenia after 1 dose in the 3 mg/kg EOW group, which was considered
possibly study-drug related, along with a serious AE of grade 3 bron-
chitis/viral syndrome that was also considered possibly study-drug
related. ABT-981 Cmax and AUC increased in a dose-proportional
manner after single doses of 0.3-10 mg/kg IV or 0.3-3 mg/kg SC and
multiple doses of 0.3-3 mg/kg SC EOW. Estimated relative bioavail-
ability after SC administration was 46%. Following EOW dosing, accu-
mulation in AUCt was approximately 2-fold. Mean terminal half-life
ranged from 10-13 days. No apparent ADA effect on ABT-981 PK was
observed. In the MAD trial, ABT-981 at all 3 doses signiﬁcantly reduced
serum levels of high-sensitivity C-reactive protein (hsCRP; P<0.05),
matrix metalloproteinase (MMP)-degraded type 1 collagen (C1M;
P<0.05 at 1 and 3 mg/kg ), IL-1a (P<0.001; Figure), and IL-1b (P<0.001;
Figure). Serum concentrations of MMP-degraded type 3 collagen (C3M;
1 and 3 mg/kg) and MMP-degraded CRP (CRPM; 3 mg/kg) demon-
strated decreasing trends (0.05<P<0.1) with ABT-981 treatment but did
not reach statistical signiﬁcance. These trends suggest that ABT-981
engaged with IL-1a and IL-1b targets and elicited an anti-inﬂammatory
response in patients with knee OA.
Conclusions: The results of these phase 1 trials demonstrate that ABT-
981 was well tolerated and had dose-proportional PK in healthy sub-
jects and patients with knee OA. The similar safety proﬁles between
ABT-981 and placebo support phase 2 investigation of ABT-981 in
